O	0	6	Effect
O	7	9	of
B-intervention	10	16	manual
I-intervention	17	22	lymph
I-intervention	23	31	drainage
O	32	34	in
O	35	43	addition
O	44	46	to
O	47	57	guidelines
O	58	61	and
B-intervention	62	70	exercise
I-intervention	71	78	therapy
O	79	81	on
B-condition	82	85	arm
I-condition	86	97	lymphoedema
O	98	105	related
O	106	108	to
O	109	115	breast
O	116	122	cancer
O	122	123	:
O	124	134	randomised
O	135	145	controlled
O	146	151	trial
O	151	152	.

O	153	155	To
O	156	165	determine
O	166	169	the
O	170	180	preventive
O	181	187	effect
O	188	190	of
O	191	197	manual
O	198	203	lymph
O	204	212	drainage
O	213	215	on
O	216	219	the
O	220	231	development
O	232	234	of
O	235	246	lymphoedema
O	247	254	related
O	255	257	to
O	258	264	breast
O	265	271	cancer
O	271	272	.

O	273	283	Randomised
O	284	290	single
O	291	298	blinded
O	299	309	controlled
O	310	315	trial
O	315	316	.

O	317	327	University
O	328	337	Hospitals
O	338	344	Leuven
O	344	345	,
B-location	346	352	Leuven
I-location	352	353	,
I-location	354	361	Belgium
O	361	362	.

B-total-participants	363	366	160
O	367	378	consecutive
B-eligibility	379	387	patients
I-eligibility	388	392	with
I-eligibility	393	399	breast
I-eligibility	400	406	cancer
I-eligibility	407	410	and
I-eligibility	411	421	unilateral
I-eligibility	422	430	axillary
I-eligibility	431	436	lymph
I-eligibility	437	441	node
I-eligibility	442	452	dissection
O	452	453	.

O	454	457	The
O	458	471	randomisation
O	472	475	was
O	476	486	stratified
O	487	490	for
O	491	495	body
O	496	500	mass
O	501	506	index
O	507	508	(
O	508	511	BMI
O	511	512	)
O	513	516	and
O	517	525	axillary
O	526	537	irradiation
O	538	541	and
O	542	551	treatment
O	552	562	allocation
O	563	566	was
O	567	576	concealed
O	576	577	.

O	578	591	Randomisation
O	592	595	was
O	596	600	done
O	601	614	independently
O	615	619	from
O	620	631	recruitment
O	632	635	and
O	636	645	treatment
O	645	646	.

O	647	655	Baseline
O	656	671	characteristics
O	672	676	were
O	677	687	comparable
O	688	695	between
O	696	699	the
O	700	706	groups
O	706	707	.

O	708	711	For
O	712	715	six
O	716	722	months
O	723	726	the
O	727	739	intervention
O	740	745	group
O	746	747	(
O	747	748	n
O	749	750	=
B-intervention-participants	751	753	79
O	753	754	)
O	755	764	performed
O	765	766	a
O	767	776	treatment
O	777	786	programme
O	787	797	consisting
O	798	800	of
O	801	811	guidelines
O	812	817	about
O	818	821	the
O	822	832	prevention
O	833	835	of
O	836	847	lymphoedema
O	847	848	,
O	849	857	exercise
O	858	865	therapy
O	865	866	,
O	867	870	and
O	871	877	manual
O	878	883	lymph
O	884	892	drainage
O	892	893	.

O	894	897	The
B-control	898	905	control
I-control	906	911	group
O	912	913	(
O	913	914	n
O	915	916	=
B-control-participants	917	919	81
O	919	920	)
O	921	930	performed
O	931	934	the
O	935	939	same
O	940	949	programme
O	950	957	without
O	958	964	manual
O	965	970	lymph
O	971	979	drainage
O	979	980	.

O	981	991	Cumulative
O	992	1001	incidence
O	1002	1004	of
O	1005	1008	arm
O	1009	1020	lymphoedema
O	1021	1024	and
O	1025	1029	time
O	1030	1032	to
O	1033	1040	develop
O	1041	1044	arm
O	1045	1056	lymphoedema
O	1056	1057	,
O	1058	1065	defined
O	1066	1068	as
O	1069	1071	an
O	1072	1080	increase
O	1081	1083	in
O	1084	1087	arm
O	1088	1094	volume
O	1095	1097	of
O	1098	1101	200
O	1102	1104	mL
O	1105	1107	or
O	1108	1112	more
O	1113	1115	in
O	1116	1119	the
O	1120	1125	value
O	1126	1132	before
O	1133	1140	surgery
O	1140	1141	.

B-iv-bin-abs	1142	1146	Four
O	1147	1155	patients
O	1156	1158	in
O	1159	1162	the
O	1163	1175	intervention
O	1176	1181	group
O	1182	1185	and
B-cv-bin-abs	1186	1189	two
O	1190	1192	in
O	1193	1196	the
O	1197	1204	control
O	1205	1210	group
O	1211	1215	were
B-outcome	1216	1220	lost
I-outcome	1221	1223	to
I-outcome	1224	1230	follow
I-outcome	1230	1231	-
I-outcome	1231	1233	up
O	1233	1234	.

O	1235	1237	At
O	1238	1240	12
O	1241	1247	months
O	1248	1253	after
O	1254	1261	surgery
O	1261	1262	,
O	1263	1266	the
B-outcome	1267	1277	cumulative
I-outcome	1278	1287	incidence
I-outcome	1288	1292	rate
I-outcome	1293	1296	for
I-outcome	1297	1300	arm
I-outcome	1301	1312	lymphoedema
O	1313	1316	was
O	1317	1327	comparable
O	1328	1335	between
O	1336	1339	the
O	1340	1352	intervention
O	1353	1358	group
O	1359	1360	(
B-iv-bin-percent	1360	1362	24
I-iv-bin-percent	1362	1363	%
O	1363	1364	)
O	1365	1368	and
O	1369	1376	control
O	1377	1382	group
O	1383	1384	(
B-cv-bin-percent	1384	1386	19
I-cv-bin-percent	1386	1387	%
O	1387	1388	)
O	1389	1390	(
O	1390	1394	odds
O	1395	1400	ratio
O	1401	1402	1
O	1402	1403	.
O	1403	1404	3
O	1404	1405	,
O	1406	1408	95
O	1408	1409	%
O	1410	1420	confidence
O	1421	1429	interval
O	1430	1431	0
O	1431	1432	.
O	1432	1433	6
O	1434	1436	to
O	1437	1438	2
O	1438	1439	.
O	1439	1440	9
O	1440	1441	;
O	1442	1443	P
O	1444	1445	=
O	1446	1447	0
O	1447	1448	.
O	1448	1450	45
O	1450	1451	)
O	1451	1452	.

O	1453	1456	The
B-outcome	1457	1461	time
I-outcome	1462	1464	to
I-outcome	1465	1472	develop
I-outcome	1473	1476	arm
I-outcome	1477	1488	lymphoedema
O	1489	1492	was
O	1493	1503	comparable
O	1504	1511	between
O	1512	1515	the
O	1516	1519	two
O	1520	1525	group
O	1526	1532	during
O	1533	1536	the
O	1537	1542	first
O	1543	1547	year
O	1548	1553	after
O	1554	1561	surgery
O	1562	1563	(
O	1563	1569	hazard
O	1570	1575	ratio
O	1576	1577	1
O	1577	1578	.
O	1578	1579	3
O	1579	1580	,
O	1581	1582	0
O	1582	1583	.
O	1583	1584	6
O	1585	1587	to
O	1588	1589	2
O	1589	1590	.
O	1590	1591	5
O	1591	1592	;
O	1593	1594	P
O	1595	1596	=
O	1597	1598	0
O	1598	1599	.
O	1599	1601	49
O	1601	1602	)
O	1602	1603	.

O	1604	1607	The
O	1608	1614	sample
O	1615	1619	size
O	1620	1631	calculation
O	1632	1635	was
O	1636	1641	based
O	1642	1644	on
O	1645	1646	a
O	1647	1655	presumed
O	1656	1660	odds
O	1661	1666	ratio
O	1667	1669	of
O	1670	1671	0
O	1671	1672	.
O	1672	1673	3
O	1673	1674	,
O	1675	1680	which
O	1681	1683	is
O	1684	1687	not
O	1688	1696	included
O	1697	1699	in
O	1700	1703	the
O	1704	1706	95
O	1706	1707	%
O	1708	1718	confidence
O	1719	1727	interval
O	1727	1728	.

O	1729	1733	This
O	1734	1738	odds
O	1739	1744	ratio
O	1745	1748	was
O	1749	1759	calculated
O	1760	1762	as
O	1763	1764	(
O	1764	1772	presumed
O	1773	1783	cumulative
O	1784	1793	incidence
O	1794	1796	of
O	1797	1808	lymphoedema
O	1809	1811	in
O	1812	1824	intervention
O	1825	1830	group
O	1830	1831	/
O	1831	1839	presumed
O	1840	1850	cumulative
O	1851	1860	incidence
O	1861	1863	of
O	1864	1866	no
O	1867	1878	lymphoedema
O	1879	1881	in
O	1882	1894	intervention
O	1895	1900	group
O	1900	1901	)
O	1901	1902	×
O	1902	1903	(
O	1903	1911	presumed
O	1912	1922	cumulative
O	1923	1932	incidence
O	1933	1935	of
O	1936	1938	no
O	1939	1950	lymphoedema
O	1951	1953	in
O	1954	1961	control
O	1962	1967	group
O	1967	1968	/
O	1968	1976	presumed
O	1977	1987	cumulative
O	1988	1997	incidence
O	1998	2000	of
O	2001	2012	lymphoedema
O	2013	2015	in
O	2016	2023	control
O	2024	2029	group
O	2029	2030	)
O	2031	2033	or
O	2034	2035	(
O	2035	2037	10
O	2037	2038	/
O	2038	2040	90
O	2040	2041	)
O	2041	2042	×
O	2042	2043	(
O	2043	2045	70
O	2045	2046	/
O	2046	2048	30
O	2048	2049	)
O	2049	2050	.

O	2051	2057	Manual
O	2058	2063	lymph
O	2064	2072	drainage
O	2073	2075	in
O	2076	2084	addition
O	2085	2087	to
O	2088	2098	guidelines
O	2099	2102	and
O	2103	2111	exercise
O	2112	2119	therapy
O	2120	2125	after
O	2126	2134	axillary
O	2135	2140	lymph
O	2141	2145	node
O	2146	2156	dissection
O	2157	2160	for
O	2161	2167	breast
O	2168	2174	cancer
O	2175	2177	is
O	2178	2186	unlikely
O	2187	2189	to
O	2190	2194	have
O	2195	2196	a
O	2197	2203	medium
O	2204	2206	to
O	2207	2212	large
O	2213	2219	effect
O	2220	2222	in
O	2223	2231	reducing
O	2232	2235	the
O	2236	2245	incidence
O	2246	2248	of
O	2249	2252	arm
O	2253	2264	lymphoedema
O	2265	2267	in
O	2268	2271	the
O	2272	2277	short
O	2278	2282	term
O	2282	2283	.

O	2284	2289	Trial
O	2290	2302	registration
O	2303	2314	Netherlands
O	2315	2320	Trial
O	2321	2329	Register
O	2330	2332	No
O	2333	2336	NTR
O	2337	2341	1055
O	2341	2342	.
